To test this hypothesis, we compared the effects of LTX-315 treatment in either wild-type or Rag2–/– (lymphocyte deficient) mice bearing B16F10 melanoma tumors (Fig. 2A and Fig. S1). Here, RAG2 is linked to melanoma.